Literature DB >> 10354973

"Rate-drop response" cardiac pacing for vasovagal syncope. Rate-Drop Response Investigators Group.

D G Benditt1, R Sutton, M Gammage, T Markowitz, J Gorski, G Nygaard, J Fetter.   

Abstract

Recent reports suggest that cardiac pacing incorporating a rate-drop response algorithm is associated with a reduction in the frequency of syncopal episodes in patients with apparent cardioinhibitory vasovagal syncope. The detection portion of the algorithm employs a programmable heart rate change-time duration "window" to both identify abrupt cardiac slowing suggestive of an imminent vasovagal event and trigger "high rate" pacing. The purpose of this study was to develop recommendations for programming the rate-drop response algorithm. Pacemaker programming, symptom status, and drug therapy were assessed retrospectively in 24 patients with recurrent vasovagal syncope of sufficient severity to warrant consideration of pacemaker treatment. In the 53 +/- 19 months prior to pacing, patients had experienced an approximate syncope burden of 1.2 events/month. During follow-up of 192 +/- 160 days, syncope recurred in 4 patients (approximate syncope burden, 0.3 events/month, p < 0.05 vs. pre-pacing), and pre-syncope in 5 patients. In these patients, rate-drop response parameters were initially set based on electrocardiographic and/or tilt-table recordings, and were re-programmed at least once in 14 (58%) individuals. A 20 beat/min window height (top rate minus bottom rate), a window width of 10 beats (61% of patients), and 2 or 3 confirmation beats (79% of patients) appeared to be appropriate in most patients. Treatment intervention rate was set to > 100 beats/min in 89% of patients, with a duration of 1 to 2 min in 79%. In conclusion, a narrow range of rate-drop response parameter settings appeared to be effective for most individuals in this group of highly symptomatic patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10354973     DOI: 10.1023/a:1009815304770

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  15 in total

1.  Guidelines for implantation of cardiac pacemakers and antiarrhythmia devices. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Pacemaker Implantation).

Authors:  L S Dreifus; C Fisch; J C Griffin; P C Gillette; J W Mason; V Parsonnet
Journal:  J Am Coll Cardiol       Date:  1991-07       Impact factor: 24.094

2.  Recommendations for pacemaker prescription for symptomatic bradycardia. Report of a working party of the British Pacing and Electrophysiology Group.

Authors: 
Journal:  Br Heart J       Date:  1991-08

3.  Dual chamber pacing aborts vasovagal syncope induced by head-up 60 degrees tilt.

Authors:  A Fitzpatrick; G Theodorakis; R Ahmed; T Williams; R Sutton
Journal:  Pacing Clin Electrophysiol       Date:  1991-01       Impact factor: 1.976

4.  Usefulness of fluoxetine hydrochloride for prevention of resistant upright tilt induced syncope.

Authors:  B P Grubb; D A Wolfe; D Samoil; P Temesy-Armos; H Hahn; L Elliott
Journal:  Pacing Clin Electrophysiol       Date:  1993-03       Impact factor: 1.976

Review 5.  Neurally mediated syncope with an update on indications and usefulness of head-upright tilt table testing and pharmacologic therapy.

Authors:  D J Kosinski; B P Grubb
Journal:  Curr Opin Cardiol       Date:  1994-01       Impact factor: 2.161

Review 6.  Cardiac pacing for prevention of recurrent vasovagal syncope.

Authors:  D G Benditt; M Petersen; K G Lurie; B P Grubb; R Sutton
Journal:  Ann Intern Med       Date:  1995-02-01       Impact factor: 25.391

7.  Reproducibility of a symptomatic response to upright tilt in young patients with unexplained syncope.

Authors:  F A Fish; J F Strasburger; D W Benson
Journal:  Am J Cardiol       Date:  1992-09-01       Impact factor: 2.778

8.  Permanent pacing for cardioinhibitory malignant vasovagal syndrome.

Authors:  M E Petersen; R Chamberlain-Webber; A P Fitzpatrick; A Ingram; T Williams; R Sutton
Journal:  Br Heart J       Date:  1994-03

9.  A placebo-controlled trial of intravenous and oral disopyramide for prevention of neurally mediated syncope induced by head-up tilt.

Authors:  C A Morillo; J W Leitch; R Yee; G J Klein
Journal:  J Am Coll Cardiol       Date:  1993-12       Impact factor: 24.094

10.  Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results.

Authors:  N Mahanonda; K Bhuripanyo; C Kangkagate; K Wansanit; B Kulchot; K Nademanee; S Chaithiraphan
Journal:  Am Heart J       Date:  1995-12       Impact factor: 4.749

View more
  6 in total

1.  Determining the optimal pacing intervention rate for vasovagal syncope.

Authors:  A S Kurbaan; A C Franzén; Z Stack; D Heaven; G Mathur; R Sutton
Journal:  J Interv Card Electrophysiol       Date:  2000-12       Impact factor: 1.900

Review 2.  Emerging indications for permanent pacing.

Authors:  D L Wolbrette; G V Naccarelli
Journal:  Curr Cardiol Rep       Date:  2000-07       Impact factor: 2.931

3.  Bradyarrhythmias.

Authors:  Thomas J. Dresing; Bruce L Wilkoff
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-08

Review 4.  Neurocardiogenic syncope: aetiology and management.

Authors:  K A Gatzoulis; P K Toutouzas
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  New approaches to the treatment and prevention of neurally mediated reflex (neurocardiogenic) syncope.

Authors:  Daniel P Melby; Joseph A Cytron; David G Benditt
Journal:  Curr Cardiol Rep       Date:  2004-09       Impact factor: 2.931

Review 6.  Pacing for Vasovagal Syncope.

Authors:  Rakesh Gopinathannair; Benjamin C Salgado; Brian Olshansky
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.